ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Bristol Myers Squibb to buy biotech firm Forbius

by Michael McCoy
August 29, 2020 | APPEARED IN VOLUME 98, ISSUE 33

 

Bristol Myers Squibb will buy the Canadian protein-engineering company Forbius for an undisclosed sum. The deal will bring inhibitors of TGF-β1 and -β3, cytokines that mediate immunosuppression and fibrosis. Such inhibitors—including Forbius’s lead compound, AVID200—are thought to act synergistically with immuno-oncology drugs. The deal does not include Forbius’s assets not related to TGF-β.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment